Generated by AI
Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines for serious oncology conditions with unmet medical need. The company works on targeted small-molecule therapies designed for genetically defined cancer patient populations, with its current pipeline centered on NXP800 and NXP900. NXP800 is being developed for specific ovarian cancer settings, while NXP900 is designed to inhibit SRC family kinases, including SRC and YES1, in solid tumors. Based in Fort Lee, New Jersey, Nuvectis Pharma operates as a single-segment biotechnology business centered on oncology drug development and clinical research.
Website1 Bridge Plaza
Fort Lee, NJ, 07024
United States
The latest articles about NVCT.
Nuvectis Pharma Inc (NVCT) outlined a bold late-stage pipeline with ciprocapan and NXP200, a cash runway into 2029, and multiple near-term catalysts despite FDA and competitive uncertainties.
Motley Fool Press Release.
Summary of Sep 29's posts. Generated by AI.
Summary of May 20's posts. Generated by AI.
Summary of Sep 29's posts. Generated by AI.
Investors talking about NVCT also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.